In May 2019, a demo at Nanjing College Healthcare facility commenced evaluating dapagliflozin to liraglutide, also to the anti-diabetic medication acarbose, for their respective outcomes on cognitive and olfactory function in 87 overweight folks whose Form two diabetic issues is inadequately managed